Atlas Venture
| Atlas Venture | |
| Company type | Private |
|---|---|
| Industry | Venture Capital |
| Founded | 1980 |
| Founder | Michiel de Haan[1] |
| Headquarters | Cambridge, Massachusetts, U.S. |
Key people | Kevin Bitterman Bruce Booth Jean-Francois Formela Michael Gladstone David Grayzel Jason Rhodes[2] |
| Products | venture capital funds |
| AUM | $2.7 billion |
Number of employees | 29 |
| Website | www.atlasventure.com |
Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located.[3] Atlas raised its fourteenth fund totaling $450 million in December 2024,[4] and raised its Opportunity Fund II totaling $300 million in September 2021.[5]
History
[edit | edit source]Originally formed in 1980 in Amsterdam as a subsidiary of NMB Bank, now part of ING Group, Atlas historically invested in both life sciences and information technology startup companies. In October 2014, Atlas announced its shift to a biotech-only venture capital firm, with the technology-focused investment team forming a new firm, Accomplice, to continue investing in information technology startups.[6][7] Previously as a diversified firm, Atlas had raised over $3.0 billion of investor commitments across nine venture capital funds. The firm raised $705 million for its 2000-vintage fifth fund, $600 million for its 2001-vintage sixth fund, $385 million for its 2006-vintage seventh fund, $283 million for its 2009-vintage eighth fund, and $265 million for its 2013-vintage ninth fund.[8][9] At its largest, the firm held European offices in London, Paris and Munich,[10] and a West Coast office based in Seattle, Washington, in addition to the Boston-area headquarters. Today, the firm operates from a single office in Cambridge, Massachusetts.[11][12]
In 2015 Atlas Venture raised its first biotech-dedicated fund, Fund X, at $280 million to invest in early stage biotech companies in the U.S. and around the world.[13] In 2017 Atlas Venture raised Fund XI at $350 million. In January 2019 Atlas Venture raised $250 million for its Opportunity Fund I, a complementary strategy focusing investment in growth financings of companies in Atlas' main fund portfolios.[14] In June 2020 Atlas Venture raised its Fund XII $400 million.[15] In March 2022 Atlas Venture raised Fund XIII at $450 million. Atlas Venture raised Fund XIV in December 2024 at $450 million.
References
[edit | edit source]- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Exclusive: Atlas Venture is splitting up. Fortune, October 2, 2014
- ^ Atlas Venture Announces $450 Million Fund XIII.
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Atlas Venture Closes New Fund with $283M, Does the Staffing Shuffle. XConomy, January 2009
- ^ Atlas Venture aims for new $500M fund Archived 2012-10-04 at the Wayback Machine. Mass High Tech, November 6, 2008
- ^ Changes in the Atlas Venture partnership. Fortune, April 8, 2014
- ^ Atlas Venture ups sticks to Boston. Tech Crunch Europe, January 19, 2010
- ^ Atlas Brings Its European Ops Back to Boston. New York Times DealBook, January 20, 2010
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
Lua error in Module:Authority_control at line 153: attempt to index field 'wikibase' (a nil value).